Most pathologists are now aware that the overwhelming majority of gastrointestinal stromal tumors (GISTs), as currently defined, express KIT (CD117) , that this expression is most often accompanied by a KIT-activating mutation, and that these formerly untreatable neoplasms can now be very effectively palliated in around 70% of cases by treatment with imatinib mesylate (STI-571; Gleevec) which binds directly to the transmembrane KIT tyrosine kinase receptor. This remarkable "bench-tobedside" story, which has evolved rapidly over the past 4 years, is a truly impressive model of how molecular medicine can significantly impact both the classification and treatment of human disease.
However, there is a potential blot on this "blue sky" horizon. Because, in most cases, one of the key criteria for a GIST to be treated with Gleevec is immunohistochemical positivity for KIT (CD117), then the Food and Drug Administration (FDA) is considering (and perhaps favoring) the requirement that a standardized immunohistochemical test for KIT be introduced. Positivity using this standardized test would in theory be required to be eligible for drug treatment. The justification for this requirement is based upon the belief that FDA approval of one (or perhaps more) immunohistochemical assays would be helpful in identifying those patients whose GIST will respond to Gleevec. The FDA-approved KIT assay, one assumes, would be regarded as a "black and white" test, more comparable to a clinical lab test, which theoretically would not be susceptible to variation or pathologist subjectivity. This despite the facts that any immunostain can only be meaningfully assessed in the context of skilled but, to some extent, subjective interpretation of the hematoxylin and eosin morphology and that immunohistochemical positivity for KIT does not equate with a diagnosis of GIST.
Not only is this premise deeply flawed, but we believe such an approach would set an unacceptable (and perhaps dangerous) precedent which could allow for abuse by commercially interested parties as more targeted therapies are introduced in the coming years. It is our strongly held opinion that FDA requirement of an arbitrary "preferred" KIT assay, while intended to facilitate diagnostic reproducibility, is at odds with the mandate of our profession to render diagnoses in the most accurate and meaningful manner. At one level, it is likely that such steps will serve to discourage the development and evaluation of new generations of KIT antibodies. At another level, we are concerned that the well-intentioned insistence on FDA-approved immunohistochemical testing misses the point. There is much in the cachet of FDA approval that bestows a false sense of consistency and objectivity and this, of itself, subverts the real challenges faced by all diagnostic labs. These challenges apply to any form of protein immunostaining, whether detected by histochemistry on a paraffin section or by chemiluminescence on a western blot.
With regard to the specific flaws in basing Gleevec therapy for GISTs on an approved assay for KIT expression, we know the following:
• that a small subset of undoubted GISTs are KITnegative but that such lesions may still have KIT mutations and be responsive to Gleevec, • that some GISTs express substantial amounts of platelet-derived growth factor receptor alpha (PDGFRA), and other receptor tyrosine kinases, that might serve as concurrent or alternative Gleevec targets, yet not be detected by KIT immunostaining, • that small numbers of other tumor types (e.g. angiosarcoma and Ewing sarcoma) may be KIT-positive, and yet show no evidence of activating KIT mutations and no evident response to Gleevec therapy (unpublished data), • that, irrespective of whether an immunostain is "standardized," individual laboratory conditions, such as tissue fixation, tissue processing, water pH and room temperature, all lead to significant variations in staining outcome-such that each laboratory invariably titrates reagents to work best in their own environment, • that interpretation of an immunohistochemical stain is, in itself, always partially subjective and there are currently no indications or guidelines that tell us what proportion of cells should be KIT-positive or how strongly positive they should be for the result to be significant, • that prior experience with an FDA-approved patented immunohistochemical test tied to a particular therapy has been, at best, a confused and unpopular debacle that has failed to gain widespread acceptance.
Whether or not we like it, the practice of anatomic pathology is to some extent subjective; although we all strive to be as objective and reproducible as possible in our daily work. This is the very nature of our profession. There are already several commercially available antibodies to KIT (CD117), with which experience has varied between different laboratories. There is also variation between labs using the same antibody, based mainly on whether antigen retrieval techniques are employed. This is the "stuff" of daily pathology practice and, judging from experience with a previously patented test, the introduction of a standardized KIT immunostaining package will not change this in any way; although it would undoubtedly generate significant income for those who market the test-particularly because the overall total volume of these is likely to be relatively low (perhaps 20-30,000 annually in the United States), likely deterring competitors from taking on the costs of development and obtaining FDA approval, which may therefore lead to a virtual monopoly and thereby drive up the cost per test. A further and very significant consideration is the abhorrent notion that a GIST patient might potentially be denied Gleevec therapy because the KIT immunostain had been performed in a routine fashion using one of the currently available antibodies, rather than with the standardized test. Pathologists may also be vulnerable to criticism (or worse) if they choose to use a commercially available antibody other then the standardised ("approved") test. It is worth noting, based on the two large clinical trials of Gleevec for GIST in the United States (totaling approximately 900 cases) to date, in which patients were entered at a variety of locations after KIT immunostaining had been performed in numerous different laboratories (large and small), that, on central pathology review so far, no more than 2 to 3% of cases (at most) have proved to be ineligible on grounds of nonreproducible KIT immunostaining. In other words, in the overwhelming majority of cases, pathologists are already doing a fine job in making accurate diagnoses of GIST, supported by reproducible KIT immunopositivity. While, indeed, it is desirable to increase objectivity in our work in any way that we can (and it may well prove to be both worthwhile and effective in future to have federally-approved guidelines for tissue fixation and staining protocols, as well as positive and negative controls for tests such as this upon which specific therapeutic decisions are based), nevertheless, the poorly justified introduction of standardized commercial tests in this context will not be in the best interests of pathology practice nor of our patients. It is to be hoped that our specialty will resist this trend promptly and with vigor.
